CAZANAT is a multi-kinase inhibitor that targets VEGFR, MET, and AXL, blocking tumour growth, angiogenesis, and metastasis.
Recommended for:
Renal cell carcinoma, hepatocellular carcinoma, medullary thyroid carcinoma.
Taken orally once daily with or without food. Tablets should be swallowed whole with water. The exact dosage and duration are determined individually by an oncologist.
Contraindications:
Side Effects: